TOR-101
undiscloseddrug program · high
Develop a safer, more effective rapalog program targeting mTOR/TORC signaling for healthspan-related disease applications, with listed focus areas including healthspan, intrinsic capacity, oncology, and respiratory tract infections.
Small-molecule rapalog / mTOR inhibition program described as more potent inhibition of TORC1 and TORC2 than first-generation rapalogs.
Listed on Tornado Therapeutics' pipeline page as a program in the company's rapalog portfolio.